Quince Therapeutics, Inc. QNCX 深 滬
已收盤 08-07 16:00:00 美东时间
30.20
+0.660
+2.23%
華盛通- 最 高30.77
- 今 開29.92
- 成交量 3.04万股
- 最 低 29.25
- 昨 收 29.54
- 總市值 2953.45万
- 52周最高 909.98
- 市盈率 靜 --
- 換手率 3.10%
- 52周最低 15.80
- 委 比 -65.29%
- 總股本 97.80万
- 歷史最高 24396.00
- 量 比 0.82
- 振 幅 5.15%
- 歷史最低 16.00
- 每 手 1
- 風險率 247.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82
Oppenheimer analyst Mazahir Alimohamed initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $82.
07-30 00:23
Quince Therapeutics Implements 1-for-20 Reverse Stock Split
Quince Therapeutics ( ($QNCX) ) has issued an update. On June 11, 2026, stockho...
06-26 21:45
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Overweight rating and announces Price Target of $4.
06-24 00:10
Quince Therapeutics Stockholders Approve Reverse Split Authorization
Quince Therapeutics ( ($QNCX) ) has provided an update. On June 11, 2026, Quinc...
06-12 06:42
Quince Therapeutics Announces Acquisition Of Orphai Therapeutics In Stock-For-Stock Deal; Quince Enters Concurrent Private Placement Agreement To Raise Up To $187M
The acquisition is structured as a stock-for-stock merger, pursuant to which all outstanding equity interests of Orphai will be exchanged based on a fixed exchange ratio for a combination of 3,258,517 shares common
05-18 21:33
Quince Therapeutics Reports Phase 2a Data For LAM-001 In Pulmonary Hypertension-Associated ILD, Demonstrated Clinically Meaningful Improvement In Multiple Assessments Of Lung Function, Including Improvement In 6MWD Of 67.4 Meters And PVR Reduction Of 33.9% At 24 Weeks; Phase 2b Trial In PH-ILD To Initiate In Mid-2026, With Topline Data Anticipated In Q1 2028
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD
05-18 21:31
